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Abstract
Background. Italian External Quality Assessment (IEQA) Program in Cytogenetics, 
established in 2001 by the Istituto Superiore di Sanità (ISS), covers both Constitutional 
and Oncohaematological diagnosis. In 2013, performance criteria were defined and ad-
opted. In this paper, we present the data from the first 4 years of activity (2013-2016) 
following the introduction of performance criteria. 
Methods. The enrollment is voluntary, fee-based and open to both public and private 
Italian laboratories. The scheme is annual and retrospective; a national panel of experts 
assess technical, analytical and interpretative performance.
Results. Overall, 95 distinct Italian laboratories participated in different Cytogenetics 
IEQA schemes over the 2013-2016 years and most of the laboratories took part in Con-
stitutional diagnosis. General hospitals and local health centers represented 40% of the 
total participants and the percentage of laboratories from Northern Regions was more 
than 45% of total participants throughout the 4-year period. As regards the performance 
evaluation, on average, 11, 9 and 23% of participants were marked as poor performers in 
Prenatal, Postnatal and Oncohaematological schemes, respectively. With regard to criti-
Address for correspondence: Maria Chiara de Stefano, Centro Nazionale Malattie Rare, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 
Rome, Italy. E-mail: mariachiara.destefano@iss.it.
Maria Chiara de Stefano, Giovanna Floridia, Federica Censi et al.
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
110
cal errors, ISCN nomenclature in Prenatal and Postnatal schemes, and interpretation 
in Oncohaematological diagnosis, were identified as main issues. On the other hand, 
karyotype errors and inadequate analysis decreased strongly, over the 4 years, in Consti-
tutional and Oncohaematological diagnosis, respectively.
Conclusions. Our data show that the introduction of poor performance encourages lab-
oratories to address critical issues, and the IEQA participation helps to improve quality 
in cytogenetic testing.
INTRODUCTION
Genetic testing is a complex and structured process, 
which requires accurate and reliable procedures as well 
as comprehensive and exhaustive reporting of results. 
Elevated quality standards are fundamental since a ge-
netic test is usually performed once in the individual’s 
lifetime and results can often imply important choices, 
not only for patients, but also for their relatives. The 
effects of diagnostic errors may lead to far-reaching 
dangerous consequences, such as therapy or reproduc-
tive inappropriate decisions. Indeed, as explained in 
Organisation for Economic Cooperation and Develop-
ment (OECD) Guidelines, all molecular genetic testing 
services should be provided and practiced under a qual-
ity assurance framework and the performance of labo-
ratories offering clinical molecular genetic tests should 
be measured [1]. In terms of continual improvement in 
quality assurance and according to ISO15189, the es-
tablishment of a quality assurance framework requires 
the development of a quality management system that 
covers both management and technical aspects, such 
as personnel and training, document control, standard 
operating procedures, validation and assuring quality 
of examination by internal quality control and External 
Quality Assessment (EQA) [2, 3]. The participation in 
EQA programs, which are interlaboratory comparisons 
by means of an external and independent body, aims to 
verify and improve the overall quality of the diagnostic 
service of a genetic laboratory. EQA acts as an essen-
tial monitoring tool to evaluate the level of the accuracy 
of the result given to the patient and the compliance 
to best practice guidelines and international standards 
[4]. Moreover, EQA has primarily an educational role 
and provides a training opportunity for laboratories by 
comparing their own skills against a “gold standard” and 
through a peer assessment.
In the European scenario, the main EQA programs 
designed to improve the quality of molecular or cytoge-
netic reports are offered by three providers, the Cytoge-
nomic External Quality Assessment Service (CEQAS), 
the European Molecular Quality Network (EMQN) 
and the Cystic Fibrosis European Network (CF Net-
work) [5-7].
In 2001, the Italian National Centre for Rare Diseas-
es (CNMR) of the Istituto Superiore di Sanità (ISS), in 
collaboration with the Italian Society of Human Genet-
ics (SIGU), launched the first trial of EQA for genetic 
testing on a national scale [8]. After the successful pi-
lot experience, the Italian EQA (IEQA) program was 
established and supported through specific research 
projects. In 2004, the governmental document “Linee 
guida per le attività di genetica medica” indicated the 
ISS as coordinator of the national EQA [9]. In 2009, 
the IEQA was recognized as institutional activity and 
was updated in 2015 by the new Official Bulletin of the 
Italian Republic [10, 11]. The enrollment is voluntary, 
fee-based and open to all Italian laboratories, both pub-
lic and private, placed on the national territory. 
Currently, IEQA offers nine different schemes in 
three distinct macro-areas: Molecular Genetics (Cystic 
Fibrosis, Beta Thalassemia and Fragile X Syndrome), 
Oncological Genetics (Adenomatous Polyposis Coli, 
Hereditary Breast and Ovarian Cancer and Lynch Syn-
drome) and Conventional Cytogenetics (Constitutional 
Cytogenetics – prenatal and postnatal diagnosis – and 
Oncohaemotological Cytogenetics).
Cytogenetic analysis is a relevant genetic testing cat-
egory: chromosomal abnormalities can lead to several 
constitutional genetic disorders and represent a char-
acteristic feature of different neoplasms. The IEQA 
program in conventional Cytogenetics is retrospective 
and covers both Constitutional and Oncohaematologi-
cal diagnosis [12]. Assessment in Cytogenetics IEQA 
program takes into account technical, analytical and in-
terpretative performance as well as reporting accuracy. 
On the basis of the experience gathered during the first 
ten years of IEQA activity, a detailed marking system 
was developed and in 2013 poor performance criteria 
were established and adopted. In agreement with the 
European EQA programs, the poor performance cri-
teria were introduced to allow objective comparisons 
between laboratories and to better identify any critical 
deficiencies based on European and/or National Cyto-
genetics Guidelines.
The purpose of this paper is to illustrate the charac-
teristics of genetic laboratories participating in Cyto-
genetics IEQA program and to present the data from 
the first 4 years of activity (2013-2016) following the 
introduction of poor performance criteria.
MATERIALS AND METHODS
Organization of the IEQA
The structural framework of IEQA has been previ-
ously described [12, 13]. IEQA is organized and coordi-
nated by the CNMR-ISS, and it is carried out in collab-
oration with SIGU. The IEQA Organizer and national 
experts provide advice on the scientific context of the 
schemes and take decisions about assessment criteria 
and the development of the Program. The enrollment 
is voluntary, fee-based and open to both public and 
private Italian laboratories. Schemes are strictly coded, 
i.e. a unique Identification Number is assigned to each 
laboratory by the scheme organizer (ISS) – the only one 
knowing the identity of the participant – and laborato-
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ries are requested to submit anonymous reports, i.e. re-
move any structure, staff and patient identifying details 
before the submission.
The program is annual and the format is retrospec-
tive: laboratories are asked to submit, in their own re-
served area on the web utility, images (3 metaphases 
and 2 karyotypes) and their final reports. Following 
specific instructions, laboratories are required to sub-
mit: one random case and one case with structural re-
arrangements in Constitutional Cytogenetics, whereas 
two cases with an abnormal karyotype are requested 
in Oncohaematological diagnosis. In the early stages 
of IEQA, laboratories were asked to send images from 
only one clinical case [12]. Subsequently, it has been 
considerate appropriate assess two clinical cases, in or-
der to have a comprehensive evaluation of laboratory’s 
skills. All the data uploaded on the web utility by labo-
ratories are evaluated by the assessors according to de-
fined and declared to participants performance criteria. 
An annual workshop is organized, where laboratories, 
assessors and the Scheme Organizer meet in order to 
discuss the results and critical issues from the EQA.
Web utility
In 2008 a dedicated web utility was developed by 
CNMR-ISS, in order to simplify communications and 
facilitate data sharing among ISS, laboratories and as-
sessors [13]. In 2015, the web utility was updated, and 
an assessment interface among assessors/ISS/labora-
tories was implemented, in order to optimize both the 
assessment and the final draft of assessment reports 
sent to laboratories. Participant laboratories receive an 
identification code and a password to access to their 
own reserved working area. Laboratories have a one 
month-period to complete the uploading process. Once 
all data have been assessed and reviewed, laboratories 
can download, in their own reserved area, a report with 
scores and comments about the analysis. 
Assessment
National experts, selected from National Societ-
ies (SIGU and Italian Society of Hematology-SIE) 
evaluate the data of the enrolled laboratories. Assess-
ment criteria are established by the CNMR-ISS and 
the panel of national experts according to current Na-
tional or International Guidelines [14, 15]. Assessment 
takes into account technical, analytical and interpreta-
tive performance. Following assessment, participating 
laboratories receive a report containing: the list of pa-
rameters and information assessed in reports and im-
ages, and the performance category assigned including 
the score achieved and also comments or suggestions. 
Since 2013, only two categories of performance in any 
single IEQA were set out: satisfactory and poor. A gen-
eral letter and a personal report are sent to each labora-
tory. The general letter includes the overall performance 
of all participants, as well as the most frequently critical 
errors and main issues of the EQA round. 
Those participants that perform poorly in Cytogenet-
ics IEQA in the current round, and at least once in the 
two previous rounds, are classified as persistent poor 
performers. Following the identification of a persistent 
poor performance, the IEQA coordinator formally no-
tifies the laboratory’s Chief advising of the recurrence 
of poor performance and providing evidence of critical 
errors made. In addition, reference guidelines and any 
suggestions for diagnostic genetic testing are supplied, 
in order to improve the quality of cases submitted by 
laboratory.
Performance criteria
Performance criteria were established by the CNMR-
ISS and by assessors, on the basis of the SIGU Guide-
lines for Cytogenetics Diagnosis and European Cyto-
geneticists Association (ECA) Guidelines for Acquired 
Cytogenetics [14, 15]. All images and reports are 
evaluated independently by 2 groups of assessors, one 
for Constitutional diagnosis and the other one for the 
Oncohaematological scheme. In Constitutional diagno-
sis, the assessment group consists of 5 national experts, 
whereas 3 assessors are required in Oncohaematological 
diagnosis. In each cytogenetics scheme, the assessors 
evaluate laboratories twice: first on-line, independently 
of each other, and then through a collective face-to-face 
discussion about laboratories performance. If there are 
discrepancies, data are assessed collectively one more 
time and final scores are reached by simultaneous vot-
ing. The assessment covers the following parameters: 
banding quality of images, karyotype/Analysis, com-
pleteness and adequacy of the analysis, correct use of 
the International System for Human Cytogenetic No-
menclature (ISCN), written description of the result, 
interpretation, report content and reporting times. The 
scores of the marking system are reported in Table 1. 
Poor performance penalty is assigned for the following 
critical errors, common to both Constitutional and On-
cohaematological schemes: inadequate banding quality, 
incorrect analysis, more than two karyotype errors, in-
correct or absent written description of the result, incor-
rect or absent interpretation, report containing inconsis-
tent statements and/or missing important information. 
Moreover, only for the Oncohaematological scheme, 
poor performance is assigned for the failure to achieve 
a threshold score, defined as total sum of the score re-
ferred to technical, analytical and interpretative perfor-
mances. The presence of one critical error, in at least one 
case, leads the laboratory to a poor performance.
RESULTS
Laboratories participating in cytogenetics IEQA
Overall, 4 rounds have been completed after the in-
troduction of poor performance criteria (from 2013 
to 2016); 95 distinct Italian laboratories participated 
in different Cytogenetics IEQA schemes and 54 con-
stantly throughout the entire period (over the 2013-
2016 years). The total number of participants is 62% of 
the Cytogenetics laboratories, as reported in the 2012 
SIGU census [16].
From the beginning of IEQA until 2009, the pro-
gram was addressed only to public laboratories and, 
in the 2013-2016 years, the general hospitals and the 
local health centers represented the majority of Ital-
ian participants (Figure 1). Comparing the affiliation of 
laboratories participating in IEQA over the 2013-2016 
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period, no substantial differences have been observed 
through the years: in addition to the public participants, 
a relevant part (with a minimum of 28% to a maximum 
of 32%) consists of commercial laboratories, followed 
by Research Hospitals (Istituti di Ricovero e Cura a 
Carattere Scientifico, IRCCS) and Universities in simi-
lar percentages (Figure 1).
With regard to geographical distribution of partici-
pants, a significant decreasing North-to-South gradient 
is evident (Table 2), according to similar distribution of 
the genetic services across the country [16, 17]. The per-
centage of laboratories localized in the Northern Regions 
was more than 45% of total participants throughout the 
4-year period, with the highest number of laboratories 
placed in Lombardia Region. As regards the two main 
Islands (Sardinia and Sicily), almost all participants came 
from Sicily. Four out of 20 Italian regions never took part 
in Cytogenetics IEQA programs (namely Valle d’Aosta, 
Abruzzo, Basilicata and Molise). The Umbria region 
participated for the first time in 2016. 
As regards the schemes distribution, most of the lab-
oratories participated in Constitutional diagnosis. Pre-
cisely, 68, 67, 64 and 59% participated to both Prenatal 
and Postnatal diagnosis EQA in 2013, 2014, 2015 and 
2016, respectively (Table 2). In addition, the Postnatal 
diagnosis was the Cytogenetics scheme with the larg-
est number of participants. The majority of laboratories 
had taken part in more than one scheme, and 17, 21, 15 
and 15% participated in all schemes offered, in 2013, 
2014, 2015 and 2016, respectively.
PERFORMANCE OF THE PARTICIPANTS IN 
CYTOGENETICS IEQA: SATISFACTORY, POOR 
AND PERSISTENT POOR PERFORMERS
Satisfactory and poor performers
In the early stages of IEQA, the assessment included 
comments about laboratories performance and sugges-
tions on how to improve the analysis; no marking sys-
tem was in place [12]. In 2013, only two categories of 
performance in any single scheme were set out: satisfac-
Table 1
General assessment criteria and marking scores for constitutional and acquired cytogenetics in Italian External Quality Assessment
EQA Cytogenetics- Assessment criteria Constitutional cytogenetics Oncohaematological cytogenetics
Max score
Banding quality of images 3 Only comment
Karyotype/analysis 4 4 or 3*
Completeness/adequacy of the analysis 2 2
Written description of the result
(ISCN nomenclature and description)
2 2
Interpretation 3 3
Report content 1 1
Reporting times 0.5 0.5
*Max score of 4 for 2013 and 2014; max score of 3 for 2015 and 2016 rounds.
Figure 1 
Distribution by affiliation of the Italian structures where genetic participating laboratories are hosted. Years of participation: 2013-
2016.
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tory and poor. Satisfactory performance was defined as 
the quality standard to be achieved by all laboratories 
performing diagnostic genetic testing. Satisfactory per-
forming laboratories were evaluated through a scoring 
system based on a specific set of assessment criteria. As 
shown in Table 1, the highest score points are related to 
analytical and interpretative skills of participants. Ac-
cordingly, the poor performance is given both in Con-
stitutional and Oncohaematological Cytogenetics when 
critical errors in either analytical or interpretation cat-
egory are identified or the report contains inconsistent 
statements. Following the introduction of performance 
criteria, 9 participants in 2013 withdrew from the EQA 
program, while 4 out of 8 laboratories, joining for the 
first time the IEQAs in 2013, participated constantly 
since then. 
In Constitutional Cytogenetics, from 2013 to 2016, 
the participants into the Prenatal scheme were 53, 52, 
51 and 45, whereas 68, 64, 70 and 65 laboratories had 
taken part in the Postnatal diagnosis. The number of 
participants in Oncohaematological scheme was 26, 28, 
26 and 26 in 2013, 2014, 2015 and 2016, respectively 
(Figure 2A).
As regards the performance evaluation, Figure 2B 
shows the number of poor versus satisfactory perform-
ers participating in IEQA different rounds and Table 3 
summarizes the most frequently critical errors leading 
to poor performance, in all reports submitted. With 
regard to Constitutional Cytogenetics, no significant 
variation in number of poor performers was observed: 
on average, 11 and 9% of prenatal and postnatal labo-
ratories, respectively. Concerning the critical errors, the 
number of karyotype errors decreased drastically over 
the 2013-2016 period: in 2016, no karyotype errors 
were identified in both Prenatal and Postnatal diag-
nosis. By contrast, the percentage of reports including 
misleading or absent ISCN nomenclature increased to 
5.5 and 3% in Prenatal and Postnatal schemes, respec-
tively. Throughout the 4-year period, the incorrect use 
of ISCN nomenclature was the most recurrent critical 
error, indicating that there is a pressing need for a more 
effective training on this issue.
As regards the Oncohaematological diagnosis, a con-
sistent number of failing performers was identified: on 
average, 23% of participants over the 2013-2016 years. 
In particular, between 2013 and 2015 years, the Onco-
haematological diagnosis was the scheme with the high-
est percentage of poor perfomers. Notably, the percent-
age of Oncohaematological poor performers increased, 
from 19% (2013) to 38% (2015). This figure fits with a 
major change in the interpretation assessment criteria 
after the publication of the ECA Guidelines [15]. In 
2015, as shown in Table 3, 27% of all reports were insuf-
ficient because of an incorrect or absent interpretation. 
Noteworthy, in 2016 the percentage of critical error re-
ferred to the interpretation decreased to 4%, contribut-
ing primarily to the strong reduction of poor performers 
to 11%. Inadequate or unassessable analysis, because 
reports are missing needed information to assess the 
complete analytical process, was found, on average, in 
about 5% of all Oncohaematological cases submitted in 
2013 and 2014.
Persistent poor performers
In 2015, in order to easily detect any poor perfor-
mance trends, and to better find out specific training 
needs, the persistent poor performance condition was 
defined. As already mentioned, those participants that 
perform poorly in Cytogenetics IEQA in the current 
round, and at least once in the two previous rounds, 
are classified as persistent poor performers. The identi-
fication of persistent poor performance does not repre-
sent another performance category by itself, but rather 
acts as an additional educational tool to draw attention 
to recurrent critical deficiencies in poor performers. 
To date, the Oncohaematological diagnosis was the 
scheme with the highest number of persistent failing 
participants, with 3 and 2 persistent poor performers 
in 2015 and 2016, respectively. In Constitutional Cyto-
genetics, a total number of 2 and 1 persistent poor per-
formers were identified in 2015 and 2016, respectively. 
Almost all the persistent poor performers failed for the 
same deficiencies which caused the previous poor per-
formance, and in particular for cytogenetic incorrect 
analysis, more than two karyotype errors, and incorrect 
or absent interpretation. Interestingly, 2 out of 3 On-
cohaematological persistent poor performers in 2015, 
achieved sufficient performance in 2016; furthermore, 
one failing performer in Postnatal diagnosis for three 
consecutive years (2013-2015), received satisfactory 
performance in 2016.
DISCUSSION
Cytogenetics is a field of genetics that concerns the 
investigation of structural and numeric chromosomal 
abnormalities, which can cause several genetic disor-
ders related to growth or development defects, such 
as intellectual disability, developmental delay, dysmor-
phisms. Chromosomal alterations can also be associ-
ated to reproductive problems leading to infertility or 
Table 2
Geographical distribution and schemes distribution of Italian 
medical genetics laboratories participating in IEQA Cytogenet-
ics Program
2013 2014 2015 2016
North 35 34 36 34
G
eo
gr
ap
hi
ca
l 
di
st
ri
bu
tio
n
Centre 16 17 16 17
South 14 11 13 12
Islands 11 12 13 11
Total 76 74 78 74
Pre/Post/Onco 13 16 12 11
Sc
he
m
es
 
di
st
ri
bu
tio
n
Pre/Post 39 34 38 33
Post/Onco 6   4 7 7
Pre 1 2 1 1
Post 10 10 13 14
Onco 7 8 7 8
Total 76 74 78 74
Pre = Prenatal scheme; Post = Postnatal scheme; Onco = Oncohaematological 
scheme.
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recurrent miscarriages. It is well known that cytogenetic 
analyses are performed also during pregnancy (i.e. cho-
rionic villus sampling and amniocentesis) since chro-
mosomal aberrations are common causes of prenatal 
death or congenital diseases (e.g. Down syndrome). 
Moreover, cytogenetics in oncohaematologic disorders 
is a crucial tool for diagnosis, prognosis, and clinical 
decision-making. 
Genetic laboratories can verify the reliability of data 
analysis and the accuracy of reporting through the par-
ticipation in national or international EQA programs. 
In Europe, the first scheme for EQA in Cytogenetics 
was established in the UK in the early 1980s [12]. In 
2014 was established the CEQAS, the European pro-
vider which offers schemes in constitutional diagnosis, 
preimplantation genetic diagnosis, haematological and 
oncological cytogenetics [5].
The Cytogenetics IEQA program, started by CNMR-
ISS in 2001, uses a retrospective format, which implies 
a general difficulty in inter-laboratory comparisons due 
to different complexity of cases submitted, whereas has 
the advantage of enabling the examination of the real 
practices of the laboratories [18]. In particular, the ret-
rospective format encourages the participation of labo-
ratories which detect chromosomal anomalies in rou-
tine clinical practice and the assessment is based on the 
genetic report effectively given to the patient.
The enrollment is on voluntary basis, although par-
Figure 2 
Participation of Italian laboratories in Cytogenetics. Program from 2013 to 2016. Total number of laboratories (A) and poor versus 
satisfactory performers (B) participating to Prenatal, Postnatal and Oncohaematological schemes, respectively.
Table 3
Poor performers and critical errors of laboratories in Prenatal, Postnatal and Oncohaematological IEQA schemes in 2013-2016. 
Data are given as percentage. Poor performers and critical errors percentages are referred to laboratories and all cases submitted, 
respectively
2013 2014 2015 2016
Pre Post Onco Pre Post Onco Pre Post Onco Pre Post Onco
Poor performers
13 10 19 8 8 25 12 10 38 13 8 11
Critical errors
Karyotype errors 5.7 1.5 0 1 0 0 2 0.7 2 0 0 0
Incorrect analysis 2 0 0 0 1.6 3.5 0 0 2 0 0.8 0
Misleading or absent ISCN 
nomenclature 
1 1.5 0 3 2 0 3 3.5 0 5.5 3 2
Inadequate banding quality 0 1.5 0 2 0 0 0 0 0 0 0 0
Incorrect or absent written 
description of the result 
0 1.5 4 0 0.8 3.5 2 1.4 0 2 0 0
Inadequate or unassessable analysis 0 0 6 0 0 3.5 0 0 0 0 0 0
Incorrect or absent interpretation* 0 0 0 1 0 9 0 0 27 0 0 4
The report contains inconsistent 
statements 
0 0 0 0 0 0 1 0.7 0 1 0 4
Pre = Prenatal scheme; Post = Postnatal scheme; Onco = Oncohaematological scheme. ISCN = International System for Human Cytogenetic Nomenclature. *In 
Oncohaematological scheme, absence of interpretation is critical error from 2015 round.
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ticipation in EQA schemes is mandatory for accredita-
tion based on ISO15189 standard, which specifies the 
requirements for quality and competence in medical 
laboratories and focuses mainly on the patient care and 
management procedures [2]. Interestingly, collected 
data show that the largest percentage (about 40%) of 
participants in Cytogenetics IEQA program, over the 
2013-2016 period, is represented by general hospitals 
or local health centers, and this highlights the constant 
effort of public health systems in order to promote edu-
cational training and continuous professional improve-
ment. Another considerable ratio, about one third of 
all participants, performed commercial activities, in line 
with the growing request for genetic tests, which are 
becoming increasingly inexpensive and widely available 
tests. Moreover, it is remarkable that the majority of 
laboratories had taken part in more than one scheme, 
suggesting that the participants appraise EQA as im-
portant tool to evaluate different cytogenetic tests of-
fered by laboratory.
The unequal distribution of participants among the 
Italian Regions, in particular the decreasing gradient 
moving from the Northern to the Southern and Islander 
Regions, is in agreement with the geographic distribu-
tion of genetic services across the country and may be 
explained by the early beginning of genetic activities in 
the Northern Regions, as reported in SIGU censuses 
[16, 17]. Regarding the participation rate in Cytogenet-
ics IEQA schemes, most of laboratories had taken part 
in constitutional diagnosis, although a slight decrease 
in the number of participants has occurred from 2013 
to 2016, in both Prenatal and Postnatal schemes. This 
reduction could be a consequence of a partial replace-
ment of constitutional cytogenetics by the molecular 
tests, primarily due to introduction and consolidation 
of Non-Invasive Prenatal Testing and progressive sub-
stitution of FISH analyses by microarrays testing [16]. 
However, recent findings in Postnatal Cytogenetics 
scheme of CEQAS provided evidence for the impor-
tance of conventional Cytogenetics (karyotyping) in the 
detection of genomic abnormalities not correctly iden-
tifiable by array and DNA-sequencing methods [19].
The setting of the marking system and poor perfor-
mance category allowed objective comparisons be-
tween participants based on assessment criteria de-
fined to achieve high standards of genetic testing in 
diagnostic laboratories. Since 2013, the identification 
of poor performance is a key element of the IEQA as-
sessment in order to differentiate between critical and 
minor errors. Overall technical performance (quality of 
metaphases, chromosomes and banding) in both con-
stitutional and oncohaematological schemes, was satis-
factory. Conversely, critical inaccuracies in the analysis 
were detected, such as karyotype errors and wrong use 
of standard cytogenetic nomenclature, (ISCN nomen-
clature) mainly for constitutional diagnosis. The ISCN 
is the standard accepted international nomenclature for 
human chromosomes and was established to answer the 
need for a common system of standardized terminology 
for human cytogenetics [20, 21]. Hence, ISCN nomen-
clature is critical for the interpretation of cytogenetic 
result, since reports should be clear, accurate and all 
information should be coherent with standardized and 
unambiguous rules.
In Oncohaematological scheme, in 2013 and 2014 
IEQA rounds, inadequacy of analysis was identified as 
a recurrent critical error. In this regard, some of poor 
performers did not include in their reports the limita-
tion of the test used. It should be pointed out that the 
level of analysis is dependent on the referral reason and, 
when the analysis is not appropriate, the interpretation 
of the result could be not correct and mislead the clini-
cian in the diagnosis or prognosis or therapy. Accord-
ing to ECA Guidelines, published at the beginning of 
2013, the reports of acquired cytogenetic abnormalities 
should include some interpretative information, such as 
the relationship of any abnormalities found to the refer-
ral reason, and association with prognosis if a robust 
association from multiple publications/international tri-
als/trial protocols exists [15]. In 2015, incorrect or ab-
sent interpretation was identified in 27% of all reports, 
contributing for the most part to the highest number of 
poor performers (38%). Conversely, in 2016, critical in-
terpretative insufficiencies were found only in 4% of all 
submitted reports, suggesting that Cytogenetics IEQA 
participation promoted internal review to address this 
issue according to the European Guidelines.
When a laboratory does not implement positive cor-
rective actions to overcome any critical deficiencies, the 
risk of becoming a persistent poor performer is high. 
Persistent poor performance is a serious alarm bell con-
cerning the diagnostic service of a genetic laboratory, 
indicating that persistent failing laboratories need fur-
ther training to overcome their recurrent critical issues. 
Hence, the identification of persistent poor performance 
aims to strongly suggest a laboratory to undertake a root 
cause analysis for recurrent failing performance. Even 
though EQA programs are not responsible for setting 
the internal quality management system, participation 
in EQAs can have a significant influence over all as-
pects of genetic testing, such as the technical quality, 
the completeness of analysis, all the information needed 
to be included in the report and also the report structure 
itself [22]. For this reason, when a laboratory receives 
a persistent poor performance, the IEQA coordinator 
will formally advise the laboratory’s Chief informing of 
recurrent critical errors made by laboratory and provid-
ing reference guidelines and suggestions on how to deal 
with specific problems. Unfortunately, following identi-
fication of a persistent poor performer, it is difficult to 
follow and monitor the implementation of corrective 
measures undertaken by laboratory, since the IEQA is 
not mandatory but only on voluntary basis. In this re-
gard, a mandatory IEQA could act through a panel to 
plan and coordinate the best support actions aiming at 
the improvement of the genetic testing performed by 
Italian diagnostic laboratories.
Furthermore, as reported by Hastings, et al. [4], a mi-
nority of poor performers and persistent poor perform-
ers, choose to drop out of the EQA program, and do not 
register for the next round. In this point, it should be 
considered that the majority of poor performers, which 
continue to enroll in Cytogenetics IEQA schemes, 
reach satisfactory results one or maximum two rounds 
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after the failing performance (to date, on average 86 
and 72% of poor performers, for Constitutional and 
Oncohaematological schemes, respectively). 
Overall, our data suggest that IEQA enrollment 
should be mandatory, and the continuous IEQA par-
ticipation is important to ensure an adequate quality 
service with reliable and accurate results of genetic test-
ing and to promote best clinical practices for the pa-
tient care. Moreover, since the relevant value of EQAs 
for continuous improving is recognized at International 
level, it has clearly emerged the need to harmonise this 
activity among different Scheme Organisers in Europe. 
Within this context, the CNMR-ISS is involved in the 
activities of EuroGentest excellence network, which 
aims at the standardisation and harmonisation of the 
quality of genetic testing across Europe. In particular, 
the Quality Sub-Committee of the European Society 
of Human Genetics, as part of EuroGentest, has pro-
moted an enlarged concerted effort to improve diagnos-
tic performance of genetic laboratories in Europe. The 
CNMR has fully supported this initiative and is actively 
involved contributing with the Italian experience of the 
IEQA to the desirable establishment of an increasingly 
coordinated approach to quality of genetic testing.
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